Generic vs. Brand-name Medicines Quiz

Generic drugs must meet lower standards than brand-name drugs to receive FDA approval.

Generic medicines do not have to demonstrate bioequivalence to the brand-name medicines.

Generic medicines are priced higher than their brand-name counterparts due to additional clinical studies.

FDA established the Drug Competition Action Plan in 2019.

Generic drugs may differ in appearance, such as shape or color, from their brand-name counterparts.

Generic medicines are not required to be the same as brand-name medicines in dosage, safety, and effectiveness.

The FDA Generic Drugs Program does not conduct pre-approval reviews for generic medicines to ensure they meet requirements.

FDA staff do not monitor approved brand-name and generic drug products to ensure they are safe, effective, and high-quality.

If negative patient side effects are reported, the FDA may not require changes in how both brand-name and generic medicines are used or manufactured.

The FDA communicates any necessary information to the public regarding medicines only when absolutely necessary.